Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers

Ehimare Akhabue, MD; Sarah S. Rittner, MA; Joseph E. Carroll, MD, PhD; Phillip M. Crawford, MS; Lydia Dant, MPH; Reesa Laws, BS; Michael C. Leo, PhD; Jon Puro, MPA-HA; Stephen D. Persell, MD, MPH

Background—Little is known about statin underutilization among diabetes mellitus patients cared for in community health centers, which tend to serve socioeconomically disadvantaged populations. Implications of the American College of Cardiology/American Heart Association (ACC/AHA) guidelines on preexisting gaps in statin treatment in this population are unclear.

Methods and Results—We included 32 440 adults (45% male, 63% nonwhite, 29% uninsured/Medicaid) aged 40 to 75 years with diabetes mellitus who received care within 16 community health center groups in 11 states in the Community Health Applied Research Network during 2013. Statin prescribing was analyzed as a function of concordance with the National Cholesterol Education Program Adult Treatment Panel 2001 and ACC/AHA 2013 guidelines. More patients’ treatments were concordant with the ACC/AHA (52.8%) versus the National Cholesterol Education Program Adult Treatment Panel (36.2%) guideline. Female sex was associated with lower concordance for both (odds ratio [OR] 0.90, CI 0.85-0.94; and OR 0.84, CI 0.80-0.88, respectively). Being insured, an Asian/Pacific Islander, or primarily Spanish speaking were associated with greater concordance for both guidelines: 35.5% (11 526/32 440) were concordant with neither guideline, the majority (79.7%) having no statin prescribed; 28.2% (9168/32 440) were concordant with ACC/AHA but not the National Cholesterol Education Program Adult Treatment Panel. 8.7% of these patients had a low-density lipoprotein cholesterol >160 mg/dL despite having a moderate- or high-intensity statin prescribed. And 11.6% (3772/32 440) were concordant with the National Cholesterol Education Program Adult Treatment Panel but not with ACC/AHA. Most of these patients had a low-density lipoprotein cholesterol between 70 and 99 mg/dL with no or a low-intensity statin prescribed.

Conclusions—Opportunities exist to improve cholesterol management in diabetes mellitus patients in community health centers. Addressing care gaps could improve cardiovascular disease prevention in this high-risk population. (J Am Heart Assoc. 2017;6: e005627. DOI: 10.1161/JAHA.117.005627.)

Key Words: cardiovascular disease prevention • cholesterol-lowering drugs • community health centers • community medicine • diabetes mellitus • guideline adherence

Statin therapy plays an important role in the primary and secondary prevention of cardiovascular events in populations at elevated risk of atherosclerotic cardiovascular disease (ASCVD).1 The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines reinforced the previous National Cholesterol Education Program Expert Panel’s Adult Treatment Panel (ATP) III identification of diabetic patients as a particularly high-risk group, recommending at least moderate intensity statin therapy in diabetic adults aged 40 to 75 and high-intensity therapy for those with ischemic vascular disease.1-3 Diabetic patients tend to have worse cardiovascular disease–related outcomes compared with nondiabetics and can significantly benefit from statin treatment.4-10 Given the increased prevalence of diabetes
Statin Underuse for DM in Community Health Centers

Akhabue et al

DOI: 10.1161/JAHA.117.005627

Clinical Perspective

What Is New?

- Previously, little was known about appropriate statin prescribing as it relates to atherosclerotic cardiovascular disease prevention in the large number of diabetes mellitus patients seen in community health centers.
- We examined electronic health record data for 32,440 adults aged 40 to 75 years with diabetes mellitus who received care within 16 community health center groups in 11 states during 2013, before the publication of the American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines.
- More patients were concordant with the ACC/AHA cholesterol treatment guideline than with the 2001 Adult Treatment Panel III guideline (52.8% versus 36.2%).
- Female sex was associated with lower concordance for both guidelines; being insured, an Asian/Pacific Islander, or primarily Spanish speaking were associated with greater concordance for both guidelines.

What Are the Clinical Implications?

- Overall, 35.5% of diabetes mellitus patients cared for at the community health centers included in this study were not receiving cholesterol management concordant with either guideline, the majority (79.7%) having no statin prescribed.
- Significant opportunities exist to improve cholesterol management among diabetes mellitus patients receiving care in community health centers.

ASCVD prevention.19 Accordingly, we examined the potential implications of the recent ACC/AHA guidelines on statin-prescribing patterns in a large cohort of DM patients seen in CHCs. In the present study we investigate whether CHC patients with DM were receiving effective ASCVD prevention as a function of level of concordance with previous ATP III and ACC/AHA guidelines.

Methods

Data Source

In this study we utilized electronic health record data to perform a cross-sectional study using data from the Community Health Applied Research Network (CHARN). CHARN is a unique community health research network that was established by the United States Department of Health and Human Services Health Resources and Services Administration in 2010. CHARN is composed of 4 research nodes and a data-coordinating center housed in the Kaiser Permanente Center for Health Research. Each research node is affiliated with an academic medical center. In turn, these research nodes are composed of 17 CHC networks located across 11 different states (AZ, CA, GA, HI, IL, MA, MD, NY, OR, SC, WA), caring for more than 500,000 patients annually. Electronic health record data pooled from participating CHCs were stored in a common data warehouse through the data-coordinating center. The clinical and sociodemographic elements included in the CHARN data warehouse were determined by CHARN researchers, clinicians, and data programmers. The decisions were based on having the data warehouse serve multiple purposes including but not limited to using electronic health record data to address relevant research questions, characterizing the safety net population, and supporting quality improvement efforts. Data validation queries were performed at the research node level before aggregation in the common data warehouse. The data-coordinating center created the final database structure, the data dictionaries, as well as data definitions and queries to validate the data provided by the nodes. Data use agreements were in place between each CHC and its respective node and between each node and the data-coordinating center. The Kaiser Permanente Northwest Institutional Review Board and the Northwestern University Institutional Review Board deemed the study exempt from review, and the other participating organizations’ review boards reviewed and approved the study or judged that it qualified to be exempt as well. A full description of CHARN can be found elsewhere.20,21

Study Population

We identified patients between the ages of 40 and 75 years with a diagnosis of DM with 1 or more clinical office visits...
between January 1, and December 31, 2013. We chose this study time period because it directly preceded publication of recent cholesterol guidelines in 2014. We included patients with 2 separate encounters with an *International Classification of Diseases 9th revision* (ICD-9) code that corresponded to a diagnosis of DM or a complication of DM (e.g., diabetic retinopathy). Patients with DM were also included if these diagnoses were present in the active problem list. Sixteen of the 17 CHC networks had all required data elements and were included in this study. Figure 1 illustrates how the study cohort was derived. The final study cohort was composed of 32,440 patients.

**Outcome Measures**

Our primary outcome was the proportion of the study population that would be concordant with either, neither, or both 2001 ATP III and 2013 ACC/AHA guidelines. We chose the 2001 ATP III rather than updated 2004 guidelines because both had the same general low-density lipoprotein cholesterol (LDL) goal, and true concordance was deemed simpler to define for the former because it lacked the optional LDL goal of <70 mg/dL. Our operational definitions for what we considered guideline-concordant prescribing practices were the following. Patients were deemed concordant with ATP III guidelines if their most recent LDL was performed in the past year and was <100 mg/dL. Patients were deemed concordant with ACC/AHA guidelines if (1) a high-intensity statin was prescribed or (2) a moderate-intensity statin was prescribed and diagnoses of ischemic vascular disease were absent or (3) the most recent LDL level was performed in the past year, was <70 mg/dL, and ischemic vascular disease was absent (Table 1).

To determine guideline concordance, we examined the medication lists of eligible patients for the presence and dose of an active statin prescription by generic name including combination pills that contained a statin. This information was used to categorize patients on December 31, 2013 as being on either no statin or low-, moderate-, or high-intensity therapy based on the medication classifications provided in the ACC/AHA cholesterol treatment guideline.1 In order to avoid underestimating the number of patients who were judged to be treated in accordance with guidelines, we made 2 assumptions in the small number of cases where the statin treatment was ambiguous: (1) patients with more than 1 active statin prescription were deemed to be on the higher-intensity statin and/or dosing, and (2) in the rare cases where no dosing information was available, statins that could be low-intensity statin and/or dosing, and (2) in the rare cases where no dosing information was available, statins that could be low or moderate or alternatively moderate or high intensity, were classified as just moderate or just high, respectively. Next, the most recent low-density lipoprotein level during the study period was determined for each patient. Finally, we classified patients as having ischemic vascular disease based on the presence of ICD-9 codes associated with coronary artery disease.

### Table 1. Operational Definitions for Concordance With ATP III and ACC/AHA Guidelines for Cholesterol Management

| Guideline | Operational Definitions for Meeting Guideline Recommendation |
|-----------|---------------------------------------------------------------|
| ATP III, 2001<sup>2</sup> | • Most recent LDL-C was performed within the past year and <100 mg/dL |
| ACC/AHA, 2013<sup>1</sup> | • High-intensity statin prescribed or • Moderate-intensity statin prescribed and no diagnosis of ischemic vascular disease or • Most recent LDL-C was performed within the past year, was <70 mg/dL and no diagnosis of ischemic vascular disease |

ACC/AHA indicates American College of Cardiology/American Heart Association 2013 Cholesterol Guidelines; ATP III, National Cholesterol Education Program Adult Treatment Panel 2001 Cholesterol Guidelines; LDL, low-density lipoprotein.
disease, previous myocardial infarction, previous revascularization, peripheral arterial disease, or ischemic stroke.

**Statistical Analysis**

To investigate our outcomes we first calculated the proportion of patients with DM who would meet the 2 operational definitions for guideline-concordant cholesterol treatment based on ATP III and ACC/AHA 2013 guidelines. These proportions were also calculated for the following demographic subgroups: sex (male, female, transgender), age, race (non-Hispanic white, Hispanic, non-Hispanic black, American Indian, Asian/Pacific Islander, multiracial, other), insurance (uninsured, Medicaid only, Medicare only, commercial only, Medicare and Medicaid ever, Medicare and commercial ever, or mixed), primary language (English, Spanish, Cantonese, Mandarin, or other), research node (1 of 4), and common clinical comorbidities that could be associated with statin prescribing.

We next sought to investigate possible associations with concordance with each guideline. To account for the intraclass correlation from the nesting of patients within CHCs and because the outcome variables were dichotomous, we used hierarchical generalized linear modeling (ie, generalized linear mixed models) with a logit link and binomial distribution, where CHC was treated as a random effect. We estimated the models using mode and curvature adaptive Gauss-Hermite quadrature integration with 10 integration points. We constructed separate univariate models for individual demographic and clinical variables and then performed multivariate analyses to evaluate unique relationships. We used dummy coding for categorical independent variables to produce odds ratios relative to a referent group. For the purposes of these analyses, CHCs were grouped into the 4 participating research nodes, the largest node (B) serving as reference group. Because the relationship with age appeared to be nonlinear, we also included a quadratic term for age.

To further investigate potential implications of the recent guidelines, we also calculated the proportion of the cohort who would be concordant with both guidelines (group A), ATP III but not ACC/AHA (group B), ACC/AHA but not ATP III (group C), or neither (group D) guideline. We then categorized each group based on LDL level and intensity of statin prescribed (none prescribed, low, moderate, high) to further clarify reasons for guideline concordance and discordance.

We performed all analyses using Stata software version 13.1 (Statacorp, College Station, TX).

**Results**

The baseline demographics of the cohort along with the proportions who met the operational definitions of the 2 cholesterol treatment guidelines are shown in Table 2. There were a total of 32,440 patients, of whom 51% (16,688) were between the ages of 51 and 64; 45% (14,456) were men, 25% (7955) Hispanic, 19% (6137) black, and 16% (5259) Asian/Pacific Islander; 20% (6492) of the cohort was primarily Spanish speaking, and 6% (1883) primarily spoke Cantonese or Mandarin. In the cohort 29% (9261) were either uninsured or had Medicaid alone.

Overall, more patients were concordant with ACC/AHA (52.8%) than with ATP III (36.2%) guidelines (P<0.001, Table 2). In general, most of the subgroups—including by sex, race, and type of insurance—had overall low concordance with both sets of guidelines and had a substantial proportion concordant with neither guideline. In the case of the black and American Indian subgroups, nearly half met neither guideline.

In multivariable adjusted analyses, women were less likely than men to be concordant with both ATP III (odds ratio [OR] [95%CI] 0.84 [0.80, 0.88], P<0.001) and the ACC/AHA (OR [95%CI] 0.90 [0.85, 0.94], P<0.001) guidelines (Table 3). Being Asian/Pacific Islander (OR [95%CI] 1.17 [1.03, 1.32], P<0.02 and 1.25 [1.10, 1.42], P<0.001, respectively) or primarily Spanish speaking (OR [95%CI] 1.33 [1.18, 1.50], P<0.001 and 1.32 [1.17, 1.48], P<0.001, respectively) associated with greater concordance with both guidelines. Black race was associated with lower concordance with ATP III (OR [95%CI] 0.77 [0.70, 0.85], P<0.001) but not with ACC/AHA. Patients carrying diagnoses of hypertension and coronary artery disease were also statistically significantly more likely to be concordant with both guidelines. Finally, having any type of health insurance, including Medicaid alone, was statistically significantly associated with greater concordance with both guidelines compared with those who were uninsured. The association of age with ATP III and ACC/AHA concordance was more approximately linear in the former case. Inclusion of a quadratic term for age improved the overall fit for the ACC/AHA model.

A substantial portion of the overall cohort (35.5%, 11,526) was not concordant with either set of guidelines; 24.5% (7974) met criteria for both guidelines; 28.2% (9168) were concordant with ACC/AHA guidelines but not the ATP III guidelines; and 11.6% (3772) were concordant with ATP III but not ACC/AHA guidelines (Figure 2).

Of the part of the cohort that was concordant with neither set of guidelines (n=11,526), 79.1% of this group had no statin prescribed regardless of LDL level (Table 4), and 60.4% had no LDL checked within the past year. Nearly all of the remainder of the patients (18.8%) were prescribed a low-intensity statin, which was the most commonly prescribed intensity of statin in this group across the range of LDL values.

Of the part of the cohort that was concordant with ATP III but not ACC/AHA guidelines (n=3772), the vast majority...
Table 2. Baseline Demographics of Diabetic Adults Seen in CHARN Community Health Centers by Proportion Meeting Either ATP III or ACC/AHA Cholesterol Management Guidelines

| Total number of patients* | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|---------------------------|---------------------------------|---------------------------------|------------------------------------|
| Total number of patients* | 32,440                          | 36.2                            | 52.8                               | 35.5                               |

**Sex**

|       | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|-------|---------------------------------|---------------------------------|------------------------------------|
| Male  | 14,456 (44.6)                   | 38.7                            | 54.7                               | 33.6                               |
| Female| 17,920 (55.2)                   | 34.2                            | 51.3                               | 37.1                               |
| Transgender | 64 (0.2)            | 40.6                            | 62.5                               | 26.6                               |

**Race/ethnicity**

| Race/ethnicity               | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|------------------------------|---------------------------------|---------------------------------|------------------------------------|
| Hispanic                     | 7,955 (24.5)                    | 38.4                            | 54.9                               | 31.8                               |
| Non-Hispanic white           | 11,765 (36.3)                   | 34.4                            | 52.5                               | 36.6                               |
| Non-Hispanic black           | 6,137 (18.9)                    | 24.6                            | 39.8                               | 49.5                               |
| Non-Hispanic American Indian | 479 (1.5)                       | 23.0                            | 41.3                               | 49.3                               |
| Non-Hispanic Asian/Pacific Islander | 5,259 (16.2)           | 52.7                            | 66.6                               | 21.2                               |
| Non-Hispanic multiracial     | 161 (0.5)                       | 38.5                            | 54.0                               | 31.1                               |
| Non-Hispanic other           | 535 (1.6)                       | 29.9                            | 53.5                               | 36.8                               |
| Unknown                      | 149 (0.5)                       | 25.5                            | 53.0                               | 40.3                               |

**Age (2013), y**

| Age (2013), y | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|---------------|---------------------------------|---------------------------------|------------------------------------|
| 40 to 50      | 9,125 (28.1)                    | 30.6                            | 45.2                               | 42.5                               |
| 51 to 64      | 16,688 (51.4)                   | 36.2                            | 54.7                               | 34.2                               |
| 65 to 75      | 6,627 (20.4)                    | 44.0                            | 58.6                               | 29.3                               |

**Hypertension**

| Hypertension | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|--------------|---------------------------------|---------------------------------|------------------------------------|
| Yes          | 22,350 (68.9)                   | 37.7                            | 56.9                               | 32.3                               |
| No           | 10,090 (31.1)                   | 32.9                            | 43.9                               | 42.8                               |

**Coronary artery disease**

| Coronary artery disease | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|-------------------------|---------------------------------|---------------------------------|------------------------------------|
| Yes                     | 3,226 (9.9)                     | 41.7                            | 72.3                               | 21.9                               |
| No                      | 29,214 (90.1)                   | 35.6                            | 50.7                               | 37.0                               |

**Ischemic cerebrovascular disease**

| Ischemic cerebrovascular disease | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|---------------------------------|---------------------------------|---------------------------------|------------------------------------|
| Yes                             | 902 (2.8)                       | 42.7                            | 34.7                               | 38.8                               |
| No                              | 31,538 (97.2)                   | 36.0                            | 53.4                               | 35.4                               |

**Peripheral arterial disease**

| Peripheral arterial disease | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|-----------------------------|---------------------------------|---------------------------------|------------------------------------|
| Yes                         | 148 (0.5)                       | 39.2                            | 71.6                               | 20.3                               |
| No                          | 32,292 (99.5)                   | 36.2                            | 52.8                               | 35.6                               |

**Primary language**

| Primary language | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|------------------|---------------------------------|---------------------------------|------------------------------------|
| English          | 22,230 (68.5)                   | 32.4                            | 49.1                               | 39.8                               |
| Spanish          | 6,492 (20.0)                    | 38.8                            | 56.2                               | 30.5                               |
| Cantonese        | 10,86 (3.3)                     | 66.5                            | 73.8                               | 12.5                               |
| Mandarin         | 797 (2.5)                       | 67.4                            | 71.5                               | 12.4                               |
| Russian          | 196 (0.6)                       | 35.2                            | 74.0                               | 18.9                               |
| Other            | 1,266 (3.9)                     | 47.5                            | 67.0                               | 23.0                               |
| Unknown          | 373 (1.1)                       | 27.6                            | 55.2                               | 38.3                               |
(84.9%) had an LDL between 70 and 99 mg/dL with no or a low-intensity statin prescribed. Only 3% of this group had an LDL <50 mg/dL (Table 5).

Of the part of the cohort that were concordant with ACC/AHA but not ATP III guidelines (n=9168), 23.7% had an LDL >130 despite being prescribed a moderate- or high-intensity statin; 8.7% of the patients had an LDL >160 despite having a moderate- or high-intensity statin prescribed (Table 6).

**Discussion**

In this study we examined statin-prescribing practices as a function of concordance with previous and current guidelines among a unique collaborative network of community health centers serving a regionally and ethnically diverse cohort of diabetic patients. To our knowledge this is the first contemporary study to examine this question on this scale in a large primarily economically vulnerable population—evidenced by the fact that 29% were either uninsured or had Medicaid alone. We demonstrate here that a suboptimal proportion of diabetic patients in CHCs met either older or newer guidelines for cholesterol treatment despite DM being a significant known risk factor for ASCVD. Regardless of application of a treatment strategy using an LDL goal or a goal based on statin dosing, significant underutilization was present. Interestingly, despite these suboptimal levels of concordance, on the eve of the implementation of the newer guidelines for statin therapy, more patients in CHC-based practices would have been concordant with new ACC/AHA criteria compared with older guidelines. This is likely due to the presence of an LDL goal in the latter. This outcome also suggests that in CHC practice, statin prescribing for DM patients may have already become more closely aligned with the principles of the newer guidelines before their publication.

In this cohort, women were less likely to be in guideline concordance than men, which is in keeping with previous data. Black race was associated with lower concordance with ATP III but not ACC/AHA criteria. However, in general nonwhite race was not associated with a lower likelihood of receiving guideline concordant therapy by either ATP III or ACC/AHA 2013 criteria. Previous studies focusing on diabetic patients in the ambulatory setting have suggested that blacks are less likely to be prescribed statin therapy than whites. However, these analyses did not focus on diabetic patients in CHCs, suggesting that the presence of such racial gaps in prescribing may depend on the clinical setting. Among all racial groups, those patients characterized as Asian/Pacific Islander had a higher likelihood of being concordant with statin-prescribing guidelines compared with non-Hispanic whites. A similar association was seen in patients with Spanish as their primary language compared with English speakers. Previous data have demonstrated very low age-adjusted rates of statin use for higher ASCVD risk patients in the Hispanic community. Further investigation is warranted.

**Table 2.** Continued

| Insurance (single) | n (% of Total Cohort) | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|--------------------|-----------------------|---------------------------------|---------------------------------|----------------------------------|
| Uninsured/self-pay only | 5319 (16.4) | 30.5 | 44.6 | 43.4 |
| Medicaid only | 3942 (12.2) | 41.3 | 55.8 | 31.4 |
| Medicare only | 2589 (8.0) | 35.2 | 52.4 | 37.1 |
| Commercial only | 2627 (8.1) | 25.5 | 45.2 | 44.8 |
| Medicare+Medicaid ever | 4683 (14.4) | 47.3 | 62.5 | 25.2 |
| Medicare+Commercial ever | 1479 (4.6) | 35.1 | 56.5 | 34.8 |
| Mixed | 11 552 (35.6) | 35.7 | 53.4 | 34.7 |
| Missing | 249 (0.8) | 24.1 | 36.5 | 56.6 |

Node

| Node | n (% of Total Cohort) | Met 2001 ATP III Guidelines (%) | Met 2013 ACC/AHA Guidelines (%) | Met Neither ATP III nor ACC/AHA (%) |
|------|-----------------------|---------------------------------|---------------------------------|----------------------------------|
| A | 5119 (15.8) | 52.9 | 66.5 | 21.0 |
| B | 11 468 (35.4) | 33.7 | 42.2 | 43.5 |
| C | 4779 (14.7) | 16.0 | 42.0 | 51.6 |
| D | 11 074 (34.1) | 39.7 | 62.2 | 27.0 |

ACC/AHA indicates American College of Cardiology/American Heart Association 2013 Cholesterol Guidelines; ATP III, National Cholesterol Education Program Adult Treatment Panel 2001 Cholesterol Guidelines; Node A, Association of Asian Pacific Community Health Organizations; Node B, Alliance of Chicago Community Health Services; Node C, Fenway Health; Node D, OCHIN.

*P<0.001 for pairwise comparison of guideline concordance based on ACC/AHA and ATP III criteria.
Table 3. Adjusted Odds Ratios for Predictors of Concordance With ATP III or ACC/AHA Cholesterol Management Guidelines

|                  | Adjusted Odds for Concordance With ATP III Guideline, OR [95%CI] | Adjusted Odds for Concordance With ACC/AHA 2013 Guideline OR [95%CI] |
|------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| **Sex**          |                                                               |                                                               |
| Male             | 1 (ref)                                                       | 1 (ref)                                                       |
| Female           | 0.84 [0.80, 0.88]                                             | 0.90 [0.85, 0.94]                                             |
| **Race**         |                                                               |                                                               |
| Non-Hispanic white | 1 (ref)                                                    | 1 (ref)                                                    |
| Hispanic         | 1.09 [0.97, 1.21]                                             | 1.12 [1.00, 1.25]                                             |
| Non-Hispanic black | 0.77 [0.70, 0.85]                                           | 0.96 [0.88, 1.04]                                           |
| American Indian  | 0.82 [0.65, 1.03]                                             | 0.92 [0.75, 1.13]                                             |
| Asian/Pacific Islander | 1.17 [1.03, 1.32]                                   | 1.25 [1.10, 1.42]                                   |
| Multiracial      | 1.06 [0.75, 1.48]                                             | 1.02 [0.72, 1.43]                                             |
| Other            | 1.00 [0.81, 1.24]                                             | 1.19 [0.98, 1.45]                                             |
| **Age**          |                                                               |                                                               |
| Linear           | 1.14 [1.11, 1.18]*                                           | 1.19 [1.15, 1.22]*                                           |
| Quadratic        |                                                               | 0.89 [0.87, 0.92]*                                           |
| Hypertension     | 1.32 [1.25, 1.40]*                                           | 1.62 [1.54, 1.71]*                                           |
| Coronary artery disease | 1.26 [1.16, 1.37]*                      | 2.33 [2.13, 2.54]*                      |
| Ischemic stroke/TIA | 1.11 [0.96, 1.28]                                        | 0.25 [0.22, 0.30]*                                        |
| Peripheral arterial disease | 0.96 [0.67, 1.37]                        | 1.60 [1.09, 2.34]*                        |
| **Primary language** |                                                               |                                                               |
| English          | 1 (ref)                                                       | 1 (ref)                                                       |
| Spanish          | 1.33 [1.18, 1.50]*                                           | 1.32 [1.17, 1.48]*                                           |
| Cantonese        | 1.22 [0.97, 1.53]                                             | 1.03 [0.81, 1.32]                                             |
| Mandarin         | 1.31 [1.02, 1.68]                                            | 1.06 [0.81, 1.37]                                            |
| Other            | 1.19 [1.03, 1.37]                                             | 1.16 [1.00, 1.34]                                             |
| **Insurance type** |                                                               |                                                               |
| Uninsured        | 1 (ref)                                                       | 1 (ref)                                                       |
| Medicaid only    | 1.47 [1.34, 1.63]*                                           | 1.49 [1.35, 1.64]*                                           |
| Medicare only    | 1.39 [1.23, 1.56]*                                           | 1.70 [1.51, 1.90]*                                           |
| Commercial only  | 1.55 [1.37, 1.77]*                                           | 1.48 [1.32, 1.66]*                                           |
| Medicare+Medicaid ever | 2.02 [1.84, 2.23]*                          | 2.13 [1.93, 2.35]*                          |
| Medicare+Commercial ever | 1.87 [1.62, 2.17]                       | 2.11 [1.84, 2.43]*                       |
| Mixed            | 1.58 [1.46, 1.71]*                                           | 1.56 [1.45, 1.69]*                                           |
| **Node**         |                                                               |                                                               |
| A                | 1.43 [0.61, 3.36]                                             | 1.68 [0.91, 3.08]                                             |
| B                | 1 (ref)                                                       | 1 (ref)                                                       |
| C                | 0.40 [0.17, 0.94]                                            | 0.86 [0.47, 1.56]                                            |
| D                | 1.15 [0.53, 2.50]                                             | 1.95 [1.13, 3.36]                                             |

ACC/AHA indicates American College of Cardiology/American Heart Association 2013 Cholesterol Guidelines; ATP III, National Cholesterol Education Program Adult Treatment Panel 2001 Cholesterol Guidelines; Node A, Association of Asian Pacific Community Health Organizations; Node B, Alliance of Chicago Community Health Services; Node C, Fenway Health; Node D, OCHIN; OR, odds ratio.

*P<0.001.

†P<0.02.

‡OR is odds ratio for 10-year increase in age.

Figure 2. Diabetic adults seen in community health centers categorized by proportion concordant with ATP III and ACC/AHA guidelines. (−) indicates not concordant with the guideline; (+), concordant with the guideline; ACC/AHA, American College of Cardiology/American Heart Association 2013 Cholesterol Guidelines; ATP III, National Cholesterol Education Program Adult Treatment Panel 2001 Cholesterol Guidelines.
The vast majority of these patients had no statin prescribed and an LDL above 100 mg/dL or had no LDL checked within the year. Although all of these patients may have been attempting therapeutic lifestyle changes to reach previous guidelines’ LDL goal before consideration of drug therapy, this group much more likely reflects evidence of substantial statin underutilization in this population without regard to LDL level. Few would argue against the assumption that at least some of these patients would have derived some benefit in the form of reduced ASCVD risk if statin therapy had been initiated. The lack of concordance with newer guidelines merely further illuminates a preexisting significant gap in statin prescribing. However, despite our focus on statin prescribing, we would be remiss not to mention that in the group that met ACC/AHA but not ATP III guidelines, despite moderate- or high-intensity therapy some of the members of this group still had an LDL >160 mg/dL. Presumably in many cases this likely represented poor medication adherence, which would be another target area of improvement.

### Table 4. Distribution of LDL Levels and Statin Intensity for DM Patients in Community Health Centers Concordant With Neither ATP III Nor ACC/AHA Guidelines (Group D, Total N=11,526)

| LDL Result During Study Year | Statin Intensity | n (% of Total) |
|------------------------------|------------------|----------------|
| None                         | No statin        | 5946 (51.6)    |
|                              | Low              | 904 (7.8)      |
|                              | Moderate         | 108 (0.9)      |
|                              | Subtotal         | 6958 (60.4)    |
| 100 to 129 mg/dL             | No statin        | 2071 (18.0)    |
|                              | Low              | 756 (6.6)      |
|                              | Moderate         | 41 (0.4)       |
|                              | Subtotal         | 2868 (24.9)    |
| 130 to 159 mg/dL             | No statin        | 851 (7.4)      |
|                              | Low              | 349 (3.0)      |
|                              | Moderate         | 23 (0.2)       |
|                              | Subtotal         | 1223 (10.6)    |
| 160 to 189 mg/dL             | No statin        | 239 (2.1)      |
|                              | Low              | 122 (1.1)      |
|                              | Moderate         | 7 (0.1)        |
|                              | Subtotal         | 368 (3.2)      |
| ≥190 mg/dL                   | No statin        | 75 (0.7)       |
|                              | Low              | 32 (0.3)       |
|                              | Moderate         | 2 (<0.1)       |
|                              | Subtotal         | 109 (0.9)      |

ACC/AHA indicates American College of Cardiology/American Heart Association 2013 Cholesterol Guidelines; ATP III, National Cholesterol Education Program Adult Treatment Panel 2001 Cholesterol Guidelines; LDL, low-density lipoprotein.

Our study findings have significant implications for both CHCs and for population-based primary and secondary prevention of cardiovascular events as a whole. In a recent analysis of a large registry of patients in cardiovascular-based

### Table 5. Distribution of LDL Levels and Statin Intensity for DM Patients in Community Health Centers Concordant With ATP III but Not ACC/AHA Guidelines (Group B, Total N=3772)

| LDL Result During Study Year | Statin Intensity | n (% of Total) |
|------------------------------|------------------|----------------|
| <50 mg/dL                    | Low              | 97 (2.6)       |
|                              | Moderate         | 18 (0.5)       |
|                              | Subtotal         | 115 (3.0)      |
| 50 to 69 mg/dL               | Low              | 307 (8.1)      |
|                              | Moderate         | 51 (1.4)       |
|                              | Subtotal         | 358 (9.5)      |
| 70 to 99 mg/dL               | None             | 2349 (62.3)    |
|                              | Low              | 854 (22.6)     |
|                              | Moderate         | 96 (2.5)       |
|                              | Subtotal         | 3299 (87.5)    |

ACC/AHA indicates American College of Cardiology/American Heart Association 2013 Cholesterol Guidelines; ATP III, National Cholesterol Education Program Adult Treatment Panel 2001 Cholesterol Guidelines; LDL, low-density lipoprotein.

### Table 6. Distribution of LDL Levels and Statin Intensity for DM Patients in Community Health Centers Concordant With ACC/AHA but Not ATP III Guidelines (Group C, Total N=9168)

| LDL Result During Study Year | Statin Intensity | n (% of Total) |
|------------------------------|------------------|----------------|
| None                         | Moderate         | 2994 (32.7)    |
|                              | High             | 1274 (13.9)    |
|                              | Subtotal         | 4268 (46.6)    |
| 100 to 129 mg/dL             | Moderate         | 1939 (21.1)    |
|                              | High             | 790 (8.6)      |
|                              | Subtotal         | 2729 (29.8)    |
| 130 to 159 mg/dL             | Moderate         | 922 (10.1)     |
|                              | High             | 451 (4.9)      |
|                              | Subtotal         | 1373 (15.0)    |
| 160 to 189 mg/dL             | Moderate         | 338 (3.7)      |
|                              | High             | 198 (2.2)      |
|                              | Subtotal         | 536 (5.8)      |
| ≥190 mg/dL                   | Moderate         | 154 (1.7)      |
|                              | High             | 108 (1.2)      |
|                              | Subtotal         | 262 (2.9)      |

ACC/AHA indicates American College of Cardiology/American Heart Association 2013 Cholesterol Guidelines; ATP III, National Cholesterol Education Program Adult Treatment Panel 2001 Cholesterol Guidelines; LDL, low-density lipoprotein.
practices, only \(\approx 60\%\) of diabetic patients who would be deemed statin eligible by new ACC/AHA guidelines were being prescribed one.\(^{16}\) Importantly, that analysis did not take into account statin type or dosing, so the concordance rate would be expected to be even lower. Our analysis, which takes into account statin type and dosing to determine intensity, also shows suboptimal concordance with both previous and current guidelines in the CHC setting. That overall concordance in our study population for ACC/AHA guidelines was not substantially worse than that in cardiovascular based practices suggests this ASCVD prevention care gap reflects a national problem. However, although statin prescribing appeared inadequate across all groups, the variable concordance within different demographic groups also suggests that underlying disparities may partially drive these substantial care gaps in the CHC population. Given the goal set by the AHA in 2010 not only to improve the cardiovascular health of all Americans by 20\% but to reduce mortality from cardiovascular disease by 20\%, these findings illustrate another potential area for significant improvement.\(^{36}\) DM has increased in incidence significantly in the past 2 decades and represents a significant risk factor for the development of cardiovascular disease.\(^{11,37}\) At the same time, low-income and minority populations carry an undue burden of DM. In our analysis we noted a disparity in statin prescribing by sex but variable odds of achieving guideline concordance by race. We also noted a benefit on guideline concordance with Medicaid and other insurance types. Among the CHC nodes, there was variation present in guideline concordance. If we had assessed care at the 16 different CHC networks that contributed data to this study individually, we might have found even greater variation. Use of this registry may enable future work to identify CHC networks that are achieving the best performance on measures such as statin prescribing. Further examination of the organizational and clinical practices at high-performing sites may ultimately identify the best approaches to improving the quality of care and addressing disparities. We believe that to achieve long-term public health goals, understanding gaps between guidelines and practice in safety net settings will be essential, especially with issues such as appropriate statin prescribing.

In this study we were able to use a large and representative cohort of patients and pool electronic health record data within the CHARN network to begin to address important questions about cardiovascular disease prevention in CHCs on more than a local level. Strengths of this study include the large, geographically diverse group of participating CHC networks. However, these results should also be viewed with several limitations in mind. One of the 17 CHC networks was excluded from our final study cohort due to missing medication data (n=2660, see Figure 1). Although our final study cohort contained nearly 93\% of the available patients who met our inclusion criteria for a DM diagnosis, confounding from excluding this CHC is a possibility. The excluded CHC was from node A and almost entirely Asian/Pacific Islander. Thus, our findings in this study for these and related language subgroups (ie, Mandarin, Cantonese) may be less representative than for the portions of population not overrepresented in the missing CHC network. Our operational definitions of guideline concordance for previous ATP III guidelines could be viewed as strict. Because previous guidelines were based on an LDL goal, we required an LDL level within the previous year when this was not mandated in the actual guidelines. We chose this approach because determining compliance based on much older LDL levels could be problematic and potentially misleading. Nevertheless, the absence of an LDL measurement was responsible for classifying a considerable number of patients as discordant with ATP III guidelines. We also assumed that when an LDL level was not present within the year that it was not checked—as opposed to the value simply being missing. This issue represents an inherent limitation of using electronic health record data in which incomplete data are always possible. We also depended on ICD-9 codes for diagnoses of ischemic vascular disease. This could lead to underestimation of the presence of these conditions depending on local practice patterns on coding. In focusing on an LDL goal <100 mg/dL as the main goal of ATP III guidelines, we also did not capture the optional goal of <70 mg/dL present in the ATP III 2004 update. We elected to do this to simplify our operational definitions of guideline concordance. In this study we also focused on statin prescribing rather than adherence with therapy. We did this because we were most interested in evaluating treatment initiation in response to specific clinical conditions as a marker of the most basic level of guideline concordance. Nevertheless, it is well known that adherence to drugs including statins for primary and secondary prevention of cardiovascular disease is generally poor.\(^{38}\) Furthermore, medication adherence can be complicated by various socioeconomic factors. Thus, it is likely that our estimates of treatment gaps are conservative and that the magnitude of these gaps is actually greater than what we show here. Further research is necessary to assess the relative importance of medication adherence as it pertains to guideline concordance of statin-prescribing practices in the CHC population.

These findings from the Community Health Applied Research Network show that significant opportunities exist to improve cholesterol management among DM patients receiving care in CHCs. The recent ACC/AHA cholesterol guidelines reemphasize preexisting gaps in statin prescribing in safety net populations. Addressing these care gaps could help reduce disparities in cardiovascular outcomes in high-risk populations in the United States.
Acknowledgments
We wish to thank and acknowledge the contributions of all participating CHARN Community Health Centers for providing their data and insight in developing this work, Mary Ann Mburnie, PhD, and Suzanne Gillespie, MS, from the CHARN Data Coordinating Center, Portland OR and Ady Oster, MD, from the Charles B. Wang Community Health Center in New York, NY. To learn more about CHARN, visit https://www.kpchr.org/charn.

Sources of Funding
This work was funded by the Health Resources and Services Administration, contract HHSH250201400001C, and by grant 1P01HS21141-01 from the Agency for Healthcare Research and Quality.

Disclosures
Dr Persell receives unrelated grant support from Pfizer, Inc. There are no other conflicts of interest to disclose.

References
1. Stone NJ, Robinson JG, Lichtenstein AH, Bailey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon DJ, Levy DJ, Lichtenstein DA, Mancini DM, Mcdonald CJ, Mcbride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Edelman KM, Jarrett NM, Labresh K, Nevo L, Nwok, Anderson JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Selik SE, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:51–545.
2. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–732.
4. Brunner NW, Ramanathan K, Wang H, Quan H, Khan NA. Effectiveness of statin prescribing on reducing mortality in South Asian, Chinese, and white patients with diabetes. Can J Cardiol. 2013;29:920–926.
5. Kearney PM, Blackwell L, Collin R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125.
6. Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006;27:2323–2329.
7. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomson MJ, Mackness MI, Charlton-Menys V, Fuller BH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696.
8. Sever PS, Poulter NR, Dahlof B, Wedel H, Collin R, Beesing S, Caufield MF, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J. Reduction in cardiovascular events with atorvastatin in 2,932 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151–1157.
9. Chou R, Dana T, Blazina I, Deo S, Forties M, Bougartos C, Grusin S, Jeanne TL. Statin Use for the Prevention of Cardiovascular Disease in Adults: A Systematic Review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality (US). 2016.
10. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ersho AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, Pignone M, Quin L, Schauer PR, Selvin E, Vafiadis DK. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2015;132:691–718.
11. Menke A, Casagranda S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314:1021–1029.
12. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Irsigler CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER III, Moyo CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wexler D, Yeh RW, Turner MB. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e630.
13. Yancy CW, Wang TY, Ventura HO, Pina IL, Vijayaraghavan K, Ferdinand KC, Haffner SL. The coalition to reduce racial and ethnic disparities in cardiovascular outcomes (CREDIT): why CREDIT matters to cardiologists. J Am Coll Cardiol. 2011;57:245–252.
14. Pencina MJ, Navar-Boggan AM, D’Agostino RB Sr, Williams K, Neely B, Sniderman AD, Peterson ED. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422–1431.
15. Muntner P, Collantiondo LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levinat EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406–1415.
16. Maddox TM, Borden WB, Tang F, Virani SS, Oetgen WJ, Mullen JB, Chan PS, Casale PN, Douglas PS, Masoudi FA, Farmer SA, Rumsfeld JS. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCORR PINNACLE Registry. J Am Coll Cardiol. 2014;64:2183–2192.
17. Karmali KN, Goff DC Jr, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:959–968.
18. Goto DM, Lee TA, Durazo-Arvizu R, Wu D, Wilder J, Reina SA, Cai J, Gonzalez F, Il, Talavera GA, Ostfeld R, Davilius ML, Statin and aspirin use among Hispanic and Latino adults at high cardiovascular risk: findings from the Hispanic Community Health Study/Study of Latinos. J Am Heart Assoc. 2016;5:e002905. DOI: 10.1161/JAHA.115.002905.
19. Egan BM, Li J, White K, Fleming DO, Connell K, Hernandez GT, Jones DW, Ferdinand KC, Sinopoli A. 2013 ACC/AHA cholesterol guideline and implications for healthy people 2020 cardiovascular disease prevention goals. J Am Heart Assoc. 2016;5:e003558. DOI: 10.1161/JAHA.116.003558.
20. Likumahuwa S, Song H, Singal R, Weir RC, Crane H, Muench J, Sim SC, DeVoe JE. Building research infrastructure in community health centers: a Community Health Applied Research Network (CHARN) report. J Am Board Fam Med. 2013;26:579–587.
21. Laws R, Suzanne G, Puro J, Van Rompaysa S, Quach T, Carroll J, Chang Weir R, Crawford P, Grasso C, Kaela E, Mckinane MA. The Community Health Applied Research Network (CHARN) data warehouse: a resource for patient-centered outcomes research and quality improvement in underserved, safety net populations. EJGEMS (Wash DC). 2014;2:1097. PMC ID: PMC4371501.
22. McCulloch CE, Searle SR, Neuhau JM, Generalized, Linear, and Mixed Models. 2nd ed. Hoboken, NJ: Wiley; 2008.
23. Rabe-Hesketh S, Skrondal A, Multilevel and Longitudinal Modeling Using Stata. 3rd ed. College Station, TX: Stata Press; 2012.
24. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods. 2nd ed. Thousand Oaks, CA: Sage Publications; 2002.
25. Guo G, Zhao HX. Multilevel modeling for binary data. Annu Rev Sociol. 2000;26:441–462.
26. Liu Q, Pierce DA. A note on Gauss-Hermite quadrature. Biometrika. 1994;81:624–629.
27. Rabe-Hesketh S, Skrondal A, Pickles A. Maximum likelihood estimation of limited and discrete dependent variable models with nested random effects. J Econom. 2005;128:301–323.
28. Virani SS, Woodard LD, Ramsey DJ, Urech TH, Akeroyd JM, Shah T, Deswal A, Bozkurt B, Ballantyne CM, Petersen LA. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015;115:21–24.
29. Safford M, Eaton L, Hawley G, Brinacombe M, Rajan M, Li H, Pogach L. Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med. 2003;163:922–928.
30. Sequist TD, Adams A, Zhang F, Ross-Degnan D,ayanian JZ. Effect of quality improvement on racial disparities in diabetes care. Arch Intern Med. 2006;166:672–681.
31. Stone NJ. Preventing atherosclerotic cardiovascular disease using American College of Cardiology and American Heart Association Prevention Guidelines: some good news, but caveats remain. *J Am Heart Assoc.* 2016;5:e004197. DOI: 10.1161/JAHA.116.004197.

32. DeFilippis AP, Young R, McEvoy JW, Michos ED, Sandfort V, Kronmal RA, McClelland RL, Blaha MJ. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. *Eur Heart J.* 2017;38:598–608.

33. Andersson C, Enserro D, Larson MG, Xanthakis V, Vasan RS. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. *J Am Heart Assoc.* 2015;4:e001888. DOI: 10.1161/JAHA.115.001888.

34. Paixao AR, Ayers CR, Berry JD, de Lemos JA, Khera A. Atherosclerotic cardiovascular disease prevention: a comparison between the third adult treatment panel and the new 2013 Treatment of Blood Cholesterol Guidelines. *Circ Cardiovasc Qual Outcomes.* 2014;7:778–779.

35. US Preventative Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Eplinig JW Jr, Garcia FA, Gillman MW, Kemper AR, Krist AH, Kurth AE, Landefeld CS, LeFevre ML, Mangione CM, Phillips WR, Owens DK, Phipps MG, Pignone MP. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. *JAMA.* 2016;316:1997–2007.

36. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenland K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schramm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. *Circulation.* 2010;121:586–613.

37. Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, Li Y, Albright AL, Gregg EW. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980–2012. *JAMA.* 2014;312:1218–1226.

38. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. *Am J Med.* 2012;125:882–887.